Results 51 to 60 of about 8,394 (135)

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi‐physiologic population pharmacokinetic approach

Clinical and Translational Science
Proguanil, an antimalarial drug, undergoes hepatic uptake by the polymorphic organic cation transporter 1 (OCT1) and is subsequently metabolized by the cytochrome P‐450 2C19 (CYP2C19) enzyme into its active metabolite, cycloguanil.
Juyoung Khwarg, Eunsol Yang, Chan Song Park, Sang Chun Ji, Kyung‐Sang Yu, SeungHwan Lee   +5 more
doaj   +1 more source

Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 337-342, August 2025.
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a ...
Chad A. Bousman, Ankita Narang, Ziad Al Bkhetan, Robyn L. Woods, Suzanne G. Orchard, Alice J. Owen, Michelle A. Fravel, Julia Gilmartin‐Thomas, Joanne Ryan, Peter D. Fransquet, Rory Wolfe, Chenglong Yu, John J. McNeil, Paul Lacaze, Michael E. Ernst   +14 more
wiley   +1 more source

Drug Exposure in Chronic Kidney Disease: It Is Not Just About the Glomerular Filtration Rate

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, Page 1-10, August 2025.
ABSTRACT Chronic kidney disease (CKD) affects over 10% of the world's population and is associated with high morbidity and mortality rates. The management of CKD is complex; CKD alters drug pharmacokinetics and pharmacodynamics and further complicates therapeutic strategies regimens.
Sophie Liabeuf, Jessica Berdougo‐Tritz, Lucie Augey, Aïcha Mbarek, Michel Jadoul, Gilbert Deray, Ziad A. Massy   +6 more
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing [PDF]

, 2014
Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large inter-patient variability partly due to genetic variations in CYP2C9.
Callaghan, J. Thomas, Caudle, Kelly E., Klein, Teri E., Lee, Ming Ta Michael, Mintzer, Scott E., Rettie, Allan E., Smith, Lisa H., Whirl-Carrillo, Michelle   +7 more
core   +3 more sources

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source

Seguridad e interacciones de los Inhibidores de la Bomba de Protones (IBP) [PDF]

, 2009
Los IBP han demostrado ser fármacos relativamente seguros después de muchos años de una amplia utilización. Las reacciones adversas con las que más frecuentemente se han asociado son leves y con escasa repercusión clínica.
Esplugues Mota, Juan Vicente
core  

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting [PDF]

, 2016
This manuscript provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using
Agúndez, José A.G., Appell, Malin Lindqvist, Bell, Gillian C., Black, John Logan, Boukouvala, Sotiria, Bruckner, Carsten, Bruckner, Carsten, Bruford, Elspeth, Caudle, Kelly, Coulthard, Sally, Daly, Ann K., Del Tredici, Andria L., den Dunnen, Johan T, Drozda, Katarzyna, Everts, Robin, Flockhart, David, Freimuth, Robert, Gaedigk, Andrea, Hachad, Houda, Hartshorne, Toinette, Ingelman-Sundberg, Magnus, Kalman, Lisa V., Klein, Teri E., Lauschke, Volker M., Maglott, Donna R., McLeod, Howard L., McMillin, Gwendolyn A., Meyer, Urs A., Müller, Daniel J., Nickerson, Deborah A., Oetting, William S., Pacanowski, Michael, Pratt, Victoria M., Relling, Mary V., Roberts, Ali, Rubinstein, Wendy S., Sangkuhl, Katrin, Schwab, Matthias, Scott, Stuart A., Sim, Sarah C, Thirumaran, Ranjit K, Toji, Lorraine H., Tyndale, Rachel, van Schaik, Ron HN, Whirl-Carrillo, Michelle, Yeo, Kiang-Teck J, Zanger, Ulrich M.   +46 more
core   +1 more source

Stroke genetics: prospects for personalized medicine. [PDF]

, 2012
Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances, primarily using the genome-wide association study approach, are transforming what we know about the genetics of multifactorial stroke, and are identifying novel stroke ...
A Gschwendtner, A Hassan, A Helgadottir, A Helgadottir, A Joutel, A Viswanathan, AB Singleton, AJ Bowes, AV Shirodkar, B Rohrer, C Bellenguez, CAPRIE Steering Committee, CS Ku, D Sibbing, DF Gudbjartsson, DJ Klionsky, DK Wysowski, DL Bhatt, DR Holmes Jr, DS Budnitz, E Flossmann, G Paré, HC Diener, HS Markus, HS Markus, Hugh S Markus, J Hardy, JA Johnson, JB Olesen, JF Meschia, JL Mega, JN Hirschhorn, JT O'Brien, L Wang, M Dichgans, M Kubo, M Serizawa, MA Ikram, MV Holmes, P Jerrard-Dunne, P Kraft, P Polychronopoulos, PC Ng, RL Sacco, RS Epstein, S Bevan, S Gretarsdottir, S Gretarsdottir, S Lanfranconi, S Olsson, S Seshadri, S Seshadri, SE Nissen, The International Warfarin Pharmacogenetics Consortium, VG Manolopoulos, VL Roger   +55 more
core   +2 more sources

Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis

United European Gastroenterology Journal, Volume 13, Issue 5, Page 719-727, June 2025.
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO).
Anita Afzali, Miguel Regueiro, Andres J. Yarur, Yamile Zabana, Siew C. Ng, Sujatha Menon, Aoibhinn McDonnell, Krisztina Lazin, Michael Keating, Abhishek Bhattacharjee, Diogo Branquinho, Eustratios Bananis, Laurent Peyrin‐Biroulet   +12 more
wiley   +1 more source

hESCs‐derived Organoids Achieve Liver Zonation Features through LSEC Modulation

Advanced Science, Volume 12, Issue 20, May 29, 2025.
This article addresses the absence of zonation features in current organoid models by co‐culturing human embryonic stem cell‐derived hepatocytes with liver sinusoidal endothelial cells exhibiting distinct zonal characteristics. It demonstrates that differential WNT2 signaling from endothelial cells modulates hepatocyte zonation and metabolic functions,
Yuying Zhang, Chenyan Huang, Lei Sun, Lyu Zhou, Yudi Niu, Kaini Liang, Bingjie Wu, Peng Zhao, Zhiqiang Liu, Xiaolin Zhou, Peng Zhang, Jianchen Wu, Jie Na, Yanan Du   +13 more
wiley   +1 more source